Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported an equity compensation grant to officer Michael Vincent Meluzio, VP and Principal Accounting Officer. He received 40,942 shares of common stock through restricted stock units that vest in equal quarterly installments over 48 months from the grant date, conditioned on continued service. He also received a separate grant of 40,942 performance stock units that may convert into common shares only if the stock trades at or above $33.00, $38.50, and $44.00 for five consecutive trading days for each tranche within 24 months, after which any unmet tranches are forfeited.

Insights

Equity Compensation Analyst

Executive receives time- and performance-based equity awards, a standard non-cash incentive structure.

Officer Michael Vincent Meluzio was granted 40,942 restricted stock units that vest quarterly over 48 months, aligning part of his compensation with sustained tenure at Cue Biopharma, Inc.. These are awarded at no cash cost to him and are not open-market purchases.

He also received 40,942 performance stock units, split into three tranches tied to stock-price hurdles of $33.00, $38.50, and $44.00. Each tranche requires the closing price to meet its target for five consecutive trading days before 24 months after grant; otherwise, unearned PSUs are forfeited. This structure links potential upside directly to longer-term share price performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Meluzio Michael Vincent

Role VP, Prin. Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,942	$0.00	--
Grant/Award	Common Stock	40,942	$0.00	--

Holdings After Transaction: Common Stock — 40,942 shares (Direct, null)

Footnotes (1)

1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

Key Figures

RSU grant size: 40,942 shares PSU grant size: 40,942 units RSU vesting period: 48 months +5 more

8 metrics

RSU grant size 40,942 shares Restricted stock units granted to Michael Vincent Meluzio

PSU grant size 40,942 units Performance stock units linked to stock-price targets

RSU vesting period 48 months Equal quarterly vesting from the grant date

PSU price hurdle 1 $33.00 Closing price per share for first tranche vesting, five consecutive trading days

PSU price hurdle 2 $38.50 Closing price per share for second tranche vesting, five consecutive trading days

PSU price hurdle 3 $44.00 Closing price per share for third tranche vesting, five consecutive trading days

PSU performance window 24 months Period from grant date before unmet PSUs are forfeited

Shares held after non-derivative grant 40,942 shares Total common stock held directly after RSU-related entry

Key Terms

restricted stock units ("RSUs"), performance stock units ("PSUs"), closing price per share, trading days, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents that grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

performance stock units ("PSUs") financial

"Represents the grant of performance stock units ("PSUs")."

closing price per share financial

"achievement of a closing price per share of $33.00, $38.50 and $44.00"

trading days financial

"for a period of five consecutive trading days."

Trading days are the specific days when a stock exchange is open and buying and selling of securities can occur, excluding weekends and exchange-declared holidays. Investors use trading days to measure performance, calculate settlement deadlines and time-sensitive events—think of them as the business hours calendar for markets, where returns, volumes and deadlines are counted only on days the market is operating.

forfeited and cancelled financial

"the PSUs shall automatically be forfeited and cancelled without consideration."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 07:34 PM Accepted by SEC EDGAR 07/10/2026 - 07:34 PM Learn about SEC filing dates

FAQ

What equity awards did CUE grant to Michael Vincent Meluzio?

Cue Biopharma granted 40,942 restricted stock units and 40,942 performance stock units to officer Michael Vincent Meluzio as part of his equity compensation package.

How do the CUE restricted stock units granted to Meluzio vest?

The 40,942 RSUs granted to Meluzio vest in equal quarterly installments over 48 months from the grant date, contingent on his continued service with Cue Biopharma.

What are the stock price targets for Meluzio’s CUE performance stock units?

Meluzio’s PSUs vest in three tranches based on Cue Biopharma’s stock closing at $33.00, $38.50, and $44.00, respectively, each for five consecutive trading days.

What is the time limit for earning the CUE performance stock units granted to Meluzio?

The PSUs must meet their stock-price targets within 24 months from the grant date. Any tranches whose targets are not achieved by then are forfeited and cancelled.

Did Michael Vincent Meluzio buy or sell CUE shares on the market in this Form 4?

No open-market trades occurred. The Form 4 reports equity awards (RSUs and PSUs) granted to Meluzio at $0.00 per share as part of his compensation.

How many CUE shares does Meluzio hold after this non-derivative grant?

Following the non-derivative grant, Meluzio is reported as holding 40,942 shares of common stock directly, reflecting the restricted stock unit award in his position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meluzio Michael Vincent

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Prin. Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		40,942(1)	A	$0	40,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	(2)	07/09/2026		A		40,942		(2)	(2)	Common Stock	40,942	$0	40,942	D

Explanation of Responses:

1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

2. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

	/s/ Michael Meluzio	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)